Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11388295 | 0.86 | ABL1 (0.51) | ABL1ALOX5PTGS1PTGS2ADRB1 | |
| SCHEMBL7714578 | 0.80 | ABL1 (0.56) | ABL1ALOX5PTGS1PTGS2MEN1 | |
| SCHEMBL7714573 | 0.79 | ABL1 (0.55) | ABL1ALOX5PTGS1PTGS2MEN1 | |
| SCHEMBL7714559 | 0.79 | ABL1 (0.59) | ABL1ALOX5PTGS1PTGS2MEN1 | |
| SCHEMBL7714570 | 0.79 | ABL1 (0.42) | ABL1ALOX5PTGS1PTGS2KDM4E | |
| SCHEMBL30450769 | 0.79 | ADRB1 (0.42) | ALOX5ADRB1ALBMEN1HTT | |
| SCHEMBL11189086 | 0.79 | ABL1 (0.42) | ABL1ALOX5PTGS1PTGS2KDM4E | |
| SCHEMBL7719105 | 0.79 | DDB1 (0.42) | ABL1ALOX5PTGS1PTGS2ADRB1 | |
| SCHEMBL907698 | 0.79 | ALOX5 (0.45) | ABL1ALOX5PTGS1PTGS2MEN1 | |
| Hydrochloric Acid SCHEMBL10956641 | 0.77 | ABL1 (0.53) | ABL1ALOX5PTGS1PTGS2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003862-A1 | 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases | MERCK SHARP & DOHME LIMITED (GB) | 2011-01-06 | — | — | US | claimed |
| EP-1987007-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LTD. (GB) | 2008-11-05 | — | — | EP | claimed |
| WO-2007093829-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-23 | — | — | WO | claimed |
| US-6387136-B1 | OXIDATION COLOR DYES AND COUPLER | L'OREAL S.A. (FR) | 2002-05-14 | — | — | US | claimed |
| EP-0974337-B1 | Keratinous fibre dyeing compositions containing 3-amino pyrazoline derivatives as coupling agents, process for dyeing and dyeing kit | OREAL (FR) | 2001-03-21 | — | — | EP | claimed |
| EP-0974337-A1 | Keratinous fibre dyeing compositions containing 3-amino pyrazoline derivatives as coupling agents, process for dyeing and dyeing kit | L'OREAL (FR) | 2000-01-26 | — | — | EP | claimed |
| US-20110003862-A1 | 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases | MERCK SHARP & DOHME LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| EP-1987007-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LTD. (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093829-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-23 | — | — | WO | disclosed |
| US-6387136-B1 | OXIDATION COLOR DYES AND COUPLER | L'OREAL S.A. (FR) | 2002-05-14 | — | — | US | disclosed |
| EP-0974337-B1 | Keratinous fibre dyeing compositions containing 3-amino pyrazoline derivatives as coupling agents, process for dyeing and dyeing kit | OREAL (FR) | 2001-03-21 | — | — | EP | disclosed |
| EP-0974337-A1 | Keratinous fibre dyeing compositions containing 3-amino pyrazoline derivatives as coupling agents, process for dyeing and dyeing kit | L'OREAL (FR) | 2000-01-26 | — | — | EP | disclosed |
| EP-0022578-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 3-AMINO-PYRAZOLINE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-06-29 | — | — | EP | disclosed |
| EP-0055418-B1 | PYRAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-02-26 | — | — | EP | disclosed |
| US-4556671-A | Pharmaceutical formulations | BURROUGHS WELLCOME CO. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0055418-A2 | Pyrazoline derivatives, processes for their preparation and pharmaceutical formulations containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-07-07 | — | — | EP | disclosed |
| US-4268436-A | OXIDATIVE DIAZOTIZATION WITH NITROSYLSULFURIC ACID, ALKALINE METAL NITRITES, OR ALKYL NITRITES | AZIENDE COLORI NAZIONALI AFFINI ACNA S.P.A. (IT) | 1981-05-19 | — | — | US | disclosed |
| EP-0022578-A1 | Pharmaceutical compositions containing 3-Amino-pyrazoline derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003862-A1 | 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases | DAO, DDO, MAOA | ABL1 1067/4885ALOX5 1140/4885PTGS1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.